Traverse 2024 Testosterone. Participants included men aged 45 to 80 years with hypogonadism and prediabetes or diabetes who were enrolled in traverse between may 23, 2018, and. The traverse trial, as the first rct powered to assess cvd events, did not show increased major adverse cardiac events (mace) incidence;
Participants included men aged 45 to 80 years with hypogonadism and prediabetes or diabetes who were enrolled in traverse between may 23, 2018, and. The study found that those men taking testosterone did not significantly improve erectile function, but it did significantly improve libido, which was sustainable all.